Recent News
Improvements in Radiation Therapies Give More Treatment Options
When it comes to different treatments for mesothelioma patients, there is no shortage of diversity, as options include chemotherapy, radiation, surgery, immune-based therapies, gene-based therapies, and more. Chemotherapy treatments cisplatin[…]
Read MoreMultiple Genetic Variants Increase Mesothelioma Risk
The term “high-risk predisposition,” is a well-known term in the cancer world that means a person could have certain genetic factors or other factors that places him or her at[…]
Read MoreMesothelioma Patients Receive Zoledronic Acid as Treatment
Known as a bisphosphonate, zoledronic acid is typically used for bone diseases such as osteoporosis, and to treat high calcium levels in the blood that can lead to other health[…]
Read MoreTime Increases Risk for Mesothelioma, Study Finds
Asbestos-related illnesses such as mesothelioma and asbestosis have been known to develop over a period of decades, affecting people years and years since their last exposure. Many studies over the[…]
Read MoreGiving Cediranib Another Chance
A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is[…]
Read MoreCalretinin More Effective Than Mesothelin in Detecting Mesothelioma Early
Mesothelioma is a rare and aggressive cancer that is difficult to diagnose because symptoms often mimic other diseases such as pulmonary fibrosis or lung cancer. Pathology reports and biopsies help[…]
Read MoreSurvival Rates Based Upon Subtypes of Mesothelioma
A recent study published in the British Journal of Cancer compared survival rates of mesothelioma patients that received their diagnosis through either cytological or by histological method for those with[…]
Read MorePhase I Clinical Trial Underway for CAR T-cell Therapy
A Phase I clinical trial for an immunotherapy treatment for malignant pleural mesothelioma and non-small cell lung cancer (NSCLC) is currently underway at the University of Pennsylvania in Philadelphia. Immunotherapy[…]
Read MorePembrolizumab Update: Aduro Biotech Collaborates with Merck
A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their[…]
Read MoreBevacizumab (Avastin): Part of a New Treatment Regimen for Mesothelioma Patients
The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is[…]
Read More
Skip to content